剪切修复偶联因子1和存活蛋白对非小细胞肺癌化学疗法敏感性的预测及其相互关系

目的 剪切修复偶联因子1(ERCC1)是核苷酸外切修复家族中的重要成员,它在核酸损伤修复过程和凋亡过程中起着重要作用;存活蛋白(Survivin)属凋亡抑制蛋白家族,是迄今发现的最强的凋亡抑制因子之一.研究中初步探索晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)中ERCC1和Sur...

Value of Excision Repair Cross-complementing 1 and Survivin in Predicting the Sensitivity of Non-small Cell Lung Cancer to Chemotherapy and Interrelationship between the Two Markers

Objective Excision repair cross-complementing 1（ERCC1）,an important member of the DNA repair gene family,plays a key role in nucleotide excision repair and apoptosis of tumor cells.Survivin,a member of inhibitor of apoptosis protein（IAP） family,is one of the most powerful factors in inhibiting apoptosis up to now.This study is to explore the value of ERCC1 and Survivin in predicting the sensitivity of non-small cell lung cancer（NSCLC） to platinum-based chemotherapy and the interrelationship between the two markers.Methods From January 2001 to June 2002,expressions of ERCC1 and Survivin of 51 advanced NSCLC patients（Ⅲ B or IV） were tested through immunohistochemistry.The patients were treated with at least 2 cycles of platinum-based chemotherapy.The curative effect was evaluated later,and the relationship among detected data,curative effect of chemotherapy and patients′ clinical parameters were analyzed with SPSS 13.0 software.Results The positive expression rates of ERCC1 and Survivin in NSCLC tissues were 58.8 %（30/51） and 76.5 %（39/51）,respectively.The effective rate of chemotherapy and 5-year survival rate for the negative group of ERCC1 were significantly higher than those for the positive group（P0.05）.The results for Survivin were similar to those for ERCC1,but there was no statistical significance（P0.05）.We also found there was no relationship between ERCC1 and Survivin by Spearman′s correlation analysis（rs=-0.088,P=0.537）.Conclusion ERCC1 and Survivin may be correlated with the development of NSCLC,and ERCC1 may be related to curative effect and prognosis of NSCLC.There was probably no mechanism of coordination or regulation in multi-drug resistance between ERCC1 and Survivin.